Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Chris Lancaster"'
Autor:
Anne J. Gonzales-Luna, Travis J. Carlson, Kierra M. Dotson, Kelley Poblete, Gabriela Costa, Julie Miranda, Chris Lancaster, Seth T. Walk, Shawn Tupy, Khurshida Begum, M. Jahangir Alam, Kevin W. Garey
Publikováno v:
Emerging Microbes and Infections, Vol 9, Iss 1, Pp 341-347 (2020)
ABSTRACTClostridioides difficile infection (CDI) is the most prevalent healthcare-associated infection in the United States and carries a significant healthcare system burden. As part of an ongoing, active surveillance system of C. difficile througho
Externí odkaz:
https://doaj.org/article/fb17572c576b443da77f041e41c28561
Publikováno v:
Open Forum Infectious Diseases. 9
Background Oral vancomycin causes profound changes to the gut microbiome due to high intra-colonic vancomycin concentrations. However, pharmacokinetics of oral vancomycin causing pharmacodynamic changes have not been explored, especially during the e
Autor:
M Jahangir Alam, Khurshida Begum, Md Ekramul Karim, Chenlin Hu, Eugenie Basseres, Chris Lancaster, Kevin W Garey
Publikováno v:
Open Forum Infectious Diseases. 9
Background Ibezapolstat (IBZ) is a non-absorbable antimicrobial currently in phase 2 clinical trials for the treatment of Clostridioides difficile infection (CDI). In vitro and human studies have shown potent activity of IBZ against C. difficile but
Autor:
Laura A McDermott, Cheleste M Thorpe, Ellie Goldstein, Audrey Schuetz, Stuart Johnson, Dale N Gerding, Karen C Carroll, Kevin W Garey, Chris Lancaster, Seth Walk, Esther Duperchy, David R Snydman, Linda Gluck, Dimitrios Bourdas
Publikováno v:
Open Forum Infectious Diseases. 9
Background We have previously reported on a US based national surveillance study from 6 geographically dispersed medical centers for the susceptibility and epidemiology of C. difficile isolates. This current survey was conducted with isolates collect
Autor:
Chris Lancaster, Taryn A Eubank, Anne J Gonzales-Luna, Chetna Dureja, Julian Hurdle, Kevin W Garey
Publikováno v:
Open Forum Infectious Diseases. 9
Background The growth and susceptibility testing of anaerobic bacteria presents many unique challenges. The Clinical Laboratory Standards Institute (CLSI) recommends performing minimum inhibitory concentration (MIC) testing for C. difficile through a
Publikováno v:
Open Forum Infectious Diseases. 9
Background Microbiome disruption associated with Clostridioides difficile infection (CDI) includes reduced metabolism of primary to secondary bile acids leading to increased likelihood of C. difficile germination and CDI recurrence. Omadacycline has
Autor:
Jacob McPherson, Chenlin Hu, Khurshida Begum, Weiqun Wang, Chris Lancaster, Anne J. Gonzales-Luna, Caroline Loveall, Michael H. Silverman, M. Jahangir Alam, Kevin W. Garey
Publikováno v:
Antimicrobial Agents and Chemotherapy. 66
Reduction of Clostridioides difficile infection (CDI) recurrence is an essential endpoint for CDI-directed antibiotic development that is often not evaluated until Phase III trials. The purpose of this project was to use a functional and metagenomic
Autor:
Bradley T. Endres, Eugenie Basseres, Diane M. Citron, Kerin L. Tyrrell, Khurshida Begum, Chris Lancaster, Yumi A. Warren, M. Jahangir Alam, Kevin W. Garey, Ellie J.C. Goldstein
Publikováno v:
Anaerobe. 79:102682
Three strictly anaerobic strains of Escherichia coli were misidentified as Fusobacterium mortiferum, due to a deletion of the hemB gene which is involved in anaerobic respiration. An unusual antimicrobial susceptibility pattern sparked the further di
Autor:
Claudia P. Schroeder, Richard L. Hengel, Ramesh V. Nathan, Timothy E. Ritter, Engels N. Obi, Chris Lancaster, Lucinda J. Van Anglen, Kevin W. Garey
Publikováno v:
Anaerobe. 77
Patients with Clostridioides difficile infection (CDI) who receive treatment at outpatient infusion centers (OICs) pose a risk for spore transmission. We investigated C. difficile contamination in the environment of CDI and non-CDI patients and evalu
Autor:
Dinh Bui, Bradley Vince, Khurshida Begum, Kevin W. Garey, Chris Lancaster, Martin Kankam, M. Jahangir Alam, Anne J Gonzales-Luna, Julie Mercier, Ming Hu, Corinne Seng Yue, Murray P. Ducharme, Michael H Silverman
Publikováno v:
Journal of Antimicrobial Chemotherapy
BackgroundClostridioides difficile infection is the most common cause of healthcare-associated infections in the USA, with limited treatment options. Ibezapolstat is a novel DNA polymerase IIIC inhibitor with in vitro activity against C. difficile.Ob